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a b s t r a c t
Percutaneous exposure to the chemical warfare nerve agent VX was evaluated in African green monkeys
(n = 9). Doses of VX (7.5–100 g/kg) were applied to the skin for 60 min and residual agent was quantiﬁed (before decontamination) to estimate the absorbed dose. Monkeys were evaluated for the presence
or absence of clinical signs of toxicity and blood was sampled periodically (30 min–12 weeks) following
exposure to measure the degree of circulating acetylcholinesterase (AChE) inhibition. Monkeys were also
evaluated for behavioral changes from VX exposure using a serial probe recognition (SPR) task. The lowest
observable adverse effect level (LOAEL) for the production of major clinical signs was determined to be
42.22 g/kg (absorbed dose estimate = 17.36 g/kg) and the LOAEL for AChE inhibition was 13.33 g/kg
(absorbed dose estimate = 6.53 g/kg). Behavioral performance was unaffected at doses that, while producing substantial AChE inhibition, did not produce clinical signs. VX represents a substantial threat as a
contact hazard and these results complement previous studies using the percutaneous route of exposure
with VX and extend the ﬁndings to a non-human primate species.
Published by Elsevier Ireland Ltd.

1. Introduction
VX (O-ethyl-S-[2-(diisopropylamino)ethyl]methylphosphonothiolate) is a fast-acting, highly potent organophosphorus chemical
warfare nerve agent. VX, like the “G” agents such as soman (GD) or
sarin (GB) can affect exposure through the inhalation route. VX can
be distinguished from the “G” agents, however, in that it is more
potent and less volatile at moderate temperatures and generally

夽 Material has been reviewed by the Walter Reed Army Institute of Research. There
is no objection to its presentation and/or publication. The opinions or assertions
contained herein are the private views of the author, and are not to be construed
as ofﬁcial, or as reﬂecting true views of the Department of the Army or the Department of Defense. Research was conducted in compliance with the Animal Welfare
Act and other Federal statutes and regulations relating to animals and experiments
involving animals and adheres to principles stated in the Guide for the Care and Use
of Laboratory Animals, NRC Publication, 1996 edition. All procedures were reviewed
and approved by the Institutes’ (WRAIR and ECBC) Animal Care and Use Committees, and performed in facilities accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care, International.
∗ Corresponding author. Tel.: +1 301 319 9721; fax: +1 301 319 9979.
E-mail address: Raymond.Genovese@US.ARMY.MIL (R.F. Genovese).

much more persistent in the environment (Sidell, 1997). Because
of these characteristics, percutaneous exposure to VX is a more substantial threat (i.e., as a contact hazard) than with the “G” agents
and is probably the route of exposure with the greatest risk of
occurrence.
VX inhibits acetylcholinesterase (AChE) resulting in an increase
in cholinergic activity that, when exposure is sufﬁcient, produces
a cascade of events that include muscle fasciculation, hypersecretion, tremor, convulsions, respiratory arrest and death (Holstege
et al., 1997). While the effects of VX have been studied in many
laboratory species including rats (Gupta et al., 1991), guinea pigs
(Shih et al., 2005), chickens (Wilson et al., 1988), and rhesus monkeys (Raveh et al., 1997), typically, these studies have looked at
an injection route of exposure, and sometimes, an inhalation route
(Genovese et al., 2007a). Several studies, however, have investigated the effects of VX after percutaneous exposure. For example,
van der Schans et al. (2003) evaluated the toxicokinetics of high
doses of VX administered via intravenous or percutaneous routes in
guinea pigs. Additional studies have looked at the electrophysiological and/or clinical manifestations of percutaneous administrations
in guinea pig (Joosen et al., 2008; Mumford et al., 2008) and pig
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(Chilcott et al., 2003). We are unaware of any previously published
studies in the literature evaluating a percutaneous exposure to VX
in non-human primates. There has been at least one case of suspected VX exposure via a percutaneous route in humans (Nozaki et
al., 1995).
The efﬁciency of the percutaneous route of exposure is susceptible to variability from a large number of factors inﬂuencing
penetration rates such as the duration of the exposure and the general permeability of the skin, which can vary across species (see
Hudson et al., 1979; Noakes and Sanderson, 1969) and can vary
within species as a function of different exposure sites (Duncan et
al., 2002; Lundy et al., 2004). Environmental temperature has also
been shown to greatly inﬂuence the absorption of VX from the percutaneous route (Craig et al., 1977). An additional factor is whether
the exposure site is occluded or whether the site is exposed to air
(e.g., McElligott, 1972).
In the present study, we investigated the effects of percutaneous
exposure to VX in African green monkeys. Rather than determining a lethal dose, our major objective was to characterize the
threshold doses producing adverse effects deﬁned in several ways.
Speciﬁcally, we wanted to determine the threshold amounts of VX
absorbed from the percutaneous exposures that would produce:
(a) inhibition of circulating AChE, (b) mild or just noticeable clinical
signs, and (c) major clinical signs and/or major behavioral performance deﬁcits. In order to estimate the amount of VX absorbed, we
applied measured amounts of VX to an exposure medium and then
quantiﬁed the amount of unabsorbed VX remaining on the exposure medium and that wiped from the surface of the skin around
the exposure site following a ﬁxed duration (60 min) exposure.
While not necessarily comprehensive, we implemented a number of procedures to hold other variables constant, such as using
the same exposure area in all subjects. Additionally, to minimize
the effects of vaporization of VX, we used an occluded exposure.
Finally, we decontaminated the site after exposure using reactive
skin decontamination lotion (RSDL) to ensure sufﬁcient safety of
the exposures that is necessary to conduct moderately long-term
evaluations with the subjects. RSDL is approved by the US Food and
Drug Administration for chemical decontamination and its use has
been shown to be an effective decontamination procedure for VX
(Bjarnason et al., 2008; Lundy et al., 2004).
2. Methods
2.1. Subjects
Nine female African green monkeys [Chlorocebus sabeus (formerly Chlorocebus
aethiops sabeus)] weighing 3.0–4.3 kg were used. Monkeys were individually housed
and maintained in a temperature (20–22◦ C)- and humidity (50 ± 10%)-controlled
vivarium under a 12-h light–dark cycle (lights on at 0600). Seven subjects were ∼10
years old and had previous pharmacological experience including organophosphorus compounds. The other two subjects were ∼4 years old and were experimentally
naïve. None of the subjects received any pharmacological agents other than that used
for anesthesia during routine physicals for at least 6 months prior to participation
in the study.
Water was available ad libitum and all subjects were fed commercial primate
rations supplemented with fresh fruit, nuts, vegetables and vitamins. The diet also
included banana-ﬂavored nutritional pellets (190 mg, Bio-Serv, Frenchtown, NJ)
earned during behavioral sessions. Animals were mildly food restricted to maintain
performance motivation by regulating food intake outside of that earned during
behavioral sessions.
2.2. Behavioral testing procedure
All subjects were tested behaviorally using a serial-probe recognition (SPR) task.
The SPR is a list memory task wherein sequences of stimuli (sample stimuli) are presented. Subsequently, the subject is presented with a choice stimulus (probe) and,
based upon substantial training, responds differentially depending upon whether
or not the probe stimulus appeared in the previous sequence. Behavioral sessions
were conducted with subjects unrestrained in their home cages using a custom
manufactured, computer-controlled, behavioral test panel that contains an interactive touch screen monitor for the presentation of visual stimuli and detection of

subject responses. Details of the apparatus and our implementation of the SPR have
been published previously (e.g., Genovese et al., 2007b). Performance on the SPR
is characterized by indices of accuracy, completed trials, and trial response time
and thus, serves as a measure of cognitive and general performance. Sessions were
normally conducted Monday–Friday at approximately the same time of day and consisted of 240 trials or until 120 min elapsed. On exposure days, the session began
approximately 120 min following the end of the exposure. All subjects had previous
experience with the SPR procedure before the start of the study.
2.3. VX exposure procedure
Chemical agent standard analytical reagent material O-ethyl-S-[2(diisopropylamino)ethyl]methylphosphonothiolate (VX or EA 1701) (Lot
#VX-U-7330-CTF-N) was stabilized by the addition of N,N-diisopropylcarbodiimide
(DICDI) (3.34% by weight). Aliquots of the agent were placed into separate vials and
refrigerated. Because undiluted VX is known to undergo autocatalytic hydrolysis
(Yang et al., 1996), the purity of the agent was determined at the time of every
exposure. That is, separate aliquots were opened for each exposure and a sample
of the material, at the time of the exposure, was also analyzed by NMR.
For NMR purity analyses, a sample (0.1 ml) was placed into a vial and weighed to
an accuracy of 0.1 mg. Internal standard triethyl phosphate (0.1 ml, >99.8% purity,
Sigma–Aldrich, part no. 538728, CAS No. 78-40-0) was added and weighed. The
mixture was then ﬂame sealed in an insert and placed in a 5 mm tube with D2 O as
a lock solvent, and the outer tube was ﬂame sealed. The tube was analyzed by 31 P
NMR for quantiﬁcation of phosphorus compounds on a Bruker Avance 300 NMR.
Percutaneous VX exposures were conducted using either one or two sites on the
skin. On the day before exposure, an area on the subject mid level on the shoulder
blade and lateral to the spine was shaved using an electric veterinary clipper and
wiped with isopropyl alcohol (IPA). Care was taken not to abrade the skin and the
site was visually inspected to insure that abrasions had not occurred. For one-site
exposures, the left side of the subject was used and for two-site exposures the left
and right sides of the subject were used. Exposures were conducted using a round
stainless steel disc (16 mm diameter and 1.5 mm thick). One side of the disc was
ﬁrst afﬁxed to an Activ-Flex Band Aid (Johnson and Johnson, Inc., Skillman, NJ).
A measured amount of VX was then applied to the disc using a calibrated digital
syringe (Hamilton Company, Reno, NV) capable of accurately delivering nanoliter
(nL) volumes (or g quantities).
Subjects were taken from the home cage using a pole and collar technique
(Anderson and Houghton, 1983), placed in a primate restraining chair, and then
into a 2000 L Hazleton exposure chamber with an ambient temperature of 21 ◦ C
(±3). The bandage containing the exposure disc was then afﬁxed to the area on the
subject previously prepared. Sufﬁcient pressure was applied during the application
of the exposure disc to ensure full contact of the disc with the skin surface. In this
regard, the exposure disc appeared to have retained good contact with the skin upon
its removal at the end of the exposure in each case. The duration of the exposure was
60 min. The entire exposure session was observed, via a video camera and monitor,
from a room adjacent to the exposure chamber.
Following the 60 min exposure, the disc was removed from the subject and
placed into a scintillation vial for quantiﬁcation of residual VX. After removing the
exposure disc, ﬁve IPA-soaked cotton applicators were used sequentially to swab
the exposure area. Each swab was placed in a test tube containing IPA for quantiﬁcation of residual VX. Subsequently, reactive skin decontamination lotion (RSDL)
(E-Z-EM Inc., Lake Success, NY) was applied to the exposure site and surrounding
area to decontaminate any remaining VX. The subject was then transported back to
a holding room for a post-exposure blood draw and then returned to the home cage.
Identical procedures were followed for two-site exposures with residual analyses
conducted for each disc and swabs at each site.
Residual VX (that retained on the exposure disc and the swabs following
exposure) was quantiﬁed utilizing isotope dilution and LC/MS/MS analysis conducted on an Agilent Technologies 1100 series Liquid Chromatograph/6410 Triple
Quadrupole mass spectrometer (Agilent Technologies, Wilmington, DE). A ten point
linear VX calibration curve was developed from analysis of standards ranging from
5.0 to 1000 ng/ml, with 250 ng/ml of the internal standard (IS) 2 H5 -O-ethyl-S[2-(diisopropylamino)ethyl]methylphosphonothioate (2 H5 -VX) in each standard.
Injections (1 l) were made with a constant ﬂow of 1 ml/min through a ZORBAX
Eclipse XDB-C18, 4.6 mm × 150 mm (5 m) analytical HPLC column with a C18 precolumn ﬁlter. The solvent gradient program was initially composed of 50% organic
phase (0.1% formic acid in methanol) and 50% aqueous phase (0.1% formic acid in
deionized water). This was then changed with a linear ramp to a composition of
99% organic/1% aqueous at 3 min and held for 1 min, then reversed back to the
initial composition from 4 to 5 min. The target compound and internal standard
peak eluted at 1.95 min. The MS/MS was equipped with an electrospray ionization
source under positive polarity. The nitrogen drying gas temperature was 350 ◦ C
at a ﬂow of 10 L/min, a nebulizer pressure of 35 psi, and a capillary voltage of
4000 V, and was operated in multiple reaction monitoring mode (MRM). For the
target analyte VX, the MRM program monitored one transition for quantitation
(m/z 268 > 128) and one for conﬁrmation (m/z 268 > 86), and for the internal standard 2 H5 -VX (synthesized in-house), one transition was monitored for quantitation
(m/z 273 > 128) (see McGuire et al., 2008). Following analysis of the standards, a
weighted regression line (1/x) was generated from the response factor (area ana-

R.F. Genovese et al. / Toxicology 279 (2011) 65–72
lyte × (concentration IS/area IS)) as a function of analyte concentration, and was
used to quantify VX. Calibration standards were analyzed weekly and stored frozen
where they remained stable for up to 6 months. Quality control samples were analyzed each day with a high, medium, and low standard analyzed along with a matrix
spike. These QC samples were required to have <15% error from the target value. An
IPA blank and a matrix blank were also run to ensure no interfering peaks were
evident.
Exposure disc samples were prepared for analysis by placing the items into
separate 20 ml glass scintillation vials with 5 ml of IPA and sonicated for 20 min.
The swab samples were placed into test tubes containing 1 ml of IPA and sonicated
for 20 min. An aliquot was removed from each vial/tube and internal standard was
added to achieve 250 ng/ml of 2 H5 -VX before analysis by LC/MS/MS.
Control exposure sessions were conducted at least seven days prior to VX exposure using distilled water and the same general exposure methods. Control sessions,
however, did not take place in a chamber used for VX exposures and IPA and RSDL
swabbing was not conducted after a control session. While the use of RSDL as part
of a control session was considered, we wanted to avoid the possibility that any
residual RSDL (either on or under the skin) might be present during the subsequent
exposure session.
All subjects received a single control exposure and a single VX exposure. VX
doses were administered using a modiﬁed up-and-down regimen (Bruce, 1985).
Decision criteria of the presence of one or more major signs of toxicity, or a substantial decrease in SPR performance, were considered when determining an increase
or decrease in subsequent exposure dose. With respect to the latter criterion, a substantial decrease in performance on the SPR was considered to occur if a 35% or
greater change in the number of completed trials or average response time, or a
20% or greater change in accuracy, was observed. These values were chosen since
they were clearly outside the normal range of baseline performance observed during the two weeks prior to exposure. Thus, the decision to increase or decrease the
dose for a subject, with regard to the dose administered to the previous subject,
was based, in large part, on whether the effects of the concentration used with the
previous subject had reached the aforementioned criteria. Six subjects received VX
and control using one exposure site (i.e., one disc) and three subjects received VX
and control using two exposure sites (i.e., two discs). The following applied doses
[i.e., the total amount placed on the exposure disc(s)] of VX in g/kg body weight
were administered: single-site, 7.50, 13.33, 23.71, 31.62, 42.22, 100.00 and two-site,
13.33, 23.71, 42.22.
2.4. Subject observation procedure
All subjects were speciﬁcally monitored for clinical signs of organophosphorus toxicity for at least 4 h following the beginning of the VX exposure. Subjects
were speciﬁcally evaluated for the presence of the following signs: ataxia, convulsions, fasciculation, hyperactivity, rhinorhea, salivation, tremors, lacrimation and
prostration. Subjects were also evaluated for any other signs that appeared to be
unusual. Additionally, subjects were observed daily, throughout the experiment,
for any general signs of ill health.
2.5. Blood sampling and cholinesterase assay procedure
Subjects were placed in a primate restraining chair for blood sampling. Approximately 1.25 ml of blood was collected from the lateral saphenous vein into sample
tubes containing EDTA (7.5%), at the following time points relative to the end of the
60-min VX exposure: 30 min, 4 h, 25 h, 72 h, 8 days, 4 weeks, 8 weeks, and 12 weeks.
Additionally, blood was collected 30 min after control exposures that occurred at
least one week before the VX exposure for each subject. Assays for AChE and butyrylcholinesterase (BChE) activity were conducted using whole blood. Details of the
procedure which is a modiﬁcation of the Ellman method (Ellman et al., 1961) have
been presented previously (Dabisch et al., 2005). Circulating AChE and BChE activity
was measured as units of activity per ml of whole blood (U/ml).

3. Results
VX purity remained stable throughout the study and NMR analyses of samples of the agent at the time of each exposure revealed
the average purity to be 92.16% by weight (range = 88.21–94.80).
Fig. 1 shows the relationship between the amounts of VX placed
on the exposure disc(s) and the estimated amount absorbed. In
this regard, the estimated amount absorbed is calculated by subtracting the amount of VX quantiﬁed on the exposure discs and
the amount of VX quantiﬁed from the post-exposure swabs of the
skin around the exposure site, from the amount of VX applied
to the exposure disc(s). A strong positive correlation between
these measures was observed for both one-site and two-site exposures (r = .99 and r = .79, respectively). The mean proportion of the
applied amount that was estimated to have been absorbed was
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Fig. 1. Relationship of applied dose of VX to absorbed dose (estimated). Each point
represents data from a single exposure in a single subject. Absorbed dose was estimated by subtracting the residual amount of VX quantiﬁed from the swabs at the
exposure site and that remaining on the exposure discs, from the amount of VX
applied to the discs. Solid symbols represent exposures using one site and open
symbols represent exposures using two sites. Dashed lines represent a linear ﬁt with
corresponding Pearson’s correlation coefﬁcient (top value is for one-site exposures
and bottom value is for two-site exposures).

41.8% (range = 30.0–49.6) for the one-site exposures and 53.3%
(range = 39.7–67.6) for the two-site exposures.
Table 1 summarizes the clinical signs of the one-site VX
exposures. The largest exposure (absorbed dose = 39.89 g/kg) produced profound clinical signs of toxicity that included severe
tremor, salivation, fasciculation and respiratory disruption. Rescue therapy was administered to this subject and although the
subject survived, recovery was minimal. A detailed report on that
subject appears in Appendix A. The next lowest dose examined
(absorbed dose = 17.36 g/kg) also produced substantial clinical
signs, including salivation and tremor, and rescue therapy was
provided. Additionally, a nearly complete inhibition (∼95%) of circulating AChE was observed at 30 min post exposure. At this dose,
however, recovery was complete with a normal appearance within
24 h. Lower doses (absorbed doses of 9.48 g/kg and 11.34 g/kg)
did not produce any clinical signs other than local fasciculation at
or around the exposure site. These two doses, however, did produce a substantial decrease in circulating AChE activity. While also
producing a substantial decrease in circulating AChE activity, an
absorbed dose of 6.53 g/kg did not produce any clinical signs of
toxicity. The lowest dose tested (absorbed dose = 2.92 g/kg) did
not produce any clinical signs and the impact on circulating AChE
was negligible.
Three doses of VX tested (42.22 g/kg, 23.71 g/kg and
13.33 g/kg) were also administered using two exposure sites
(i.e., by splitting the application between the two exposure discs).
These applied doses resulted in absorbed doses of 16.74 g/kg,
16.39 g/kg and 7.08 g/kg, respectively. Thus, the proportion of
the applied dose that was absorbed in the two-site exposures was
similar to that of the one-site exposures (see Table 1). None of the
two-site exposures, however, produced any clinical signs of toxicity, including local fasciculation. Furthermore, while all three of
the two-site exposures produced inhibition of circulating AChE, the
peak amount of AChE inhibition observed (67.8%, 15.2% and 13.6%,
respectively) was less than that observed with the corresponding
one-site exposures.
Except for the two highest doses of VX examined, SPR performance was not substantially degraded after all other doses. That
is, performance on the SPR on the day of exposure and subsequent
days did not meet the criteria for disruption (see Section 2) and
was, in general, within the range of baseline values for accuracy,
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Table 1
Effects of single percutaneous (one-site) exposures to VX in African green monkeys.
Absorbed dose
(g/kg)

Applied dose
(g/kg)

Effects

Rescue therapy

39.89

100.00

Atropine, 2-PAM, diazepam
administered multiple times

17.36

42.22

11.34

23.71

9.48

31.62

6.53

13.33

2.92

7.50

Clinical signs within 30 min of exposure.
Severe signs by the end of the 60 min exposure
including whole body tremors, profuse
salivation, fasciculation, prostration and
shallow/irregular/labored breathing. Minimal
recovery observed.
Clinical signs including salivation, tremor and
fasciculation. AChE inhibition ∼95% at 30 min
post exposure. Recovery (including behavioral
performance) 24 h post exposure.
Local fasciculation. No other clinical signs. No
SPR deﬁcit. Peak AChE inhibition ∼65%, 4 h
post-exposure.
Local fasciculation. No other clinical signs. No
SPR deﬁcit. Peak AChE inhibition ∼59%, 4 h
post exposure
No clinical signs. No SPR deﬁcit. Peak AChE
inhibition ∼35%, 4 h post exposure.
No clinical signs. No SPR deﬁcit. Peak AChE
inhibition ∼8%, 4 h post exposure.

completed trials, and trial response time. The subject receiving the
highest dose had persistent deﬁcits in function (see Appendix A)
which precluded further SPR testing after exposure. The subject
receiving an absorbed dose of 17.36 g/kg was symptomatic and
received IM injections of atropine sulfate (0.29 mg/kg), 2-PAM HCl
(17.4 mg/kg) and diazepam (1.0 mg.kg) after the exposure as an
antidote treatment and no SPR session was conducted on the day
of exposure. Performance on the following day, and subsequent
days, was not degraded. In general, all surviving subjects continued
to maintain performance on the SPR during the weeks following
exposure and no delayed performance deﬁcits were observed.
Average cholinesterase activity measured from blood sampled
after control exposure sessions was 3.90 U/ml (±0.12 SEM) for AChE
and 0.47 U/ml (±0.03 SEM) for BChE. Fig. 2 shows AChE activity (as
a percentage of control values) from blood samples taken 30 min,
4 h and 25 h following exposure in all subjects except the subject receiving the highest dose (see Appendix A). VX exposures
produced dose-dependent decreases in circulating AChE activity
with positive correlation coefﬁcients observed between dose and
activity at all three time points. AChE inhibition was, in general,
greater at 4 h after exposure as compared to either 30 min or
25 h after exposure. One subject receiving a 17.36 g/kg absorbed
dose showed peak inhibition of AChE activity at 30 min post exposure. That subject, however, received rescue therapy that included
the oxime 2-PAM HCl (which would be expected to regenerate
VX-inhibited AChE) after the 30 min post-exposure blood sample
but before the 4 h blood sample. Additionally, the one-site exposures produced more AChE inhibition than the closest counterpart
absorbed dose administered as a two-site exposure in every case,
except for the aforementioned subject after 2-PAM HCl was administered. Recovery of AChE activity was complete in all surviving
subjects by 4 weeks following exposure with the mean activity
of 101.78 (±3.58 SEM) percent of control values. Fig. 3 shows the
corresponding BChE activity values (as a percentage of control values) from blood samples taken at the same time points as Fig. 2.
VX exposures also produced dose-dependent decreases in circulating BChE activity with positive correlation coefﬁcients observed
between dose and activity at all three time points. As with AChE,
BChE inhibition was, in general, greater at 4 h after exposure as
compared to either 30 min or 25 h after exposure. In general, however, BChE inhibition appeared to be less than for AChE. Also similar
to what was observed with AChE, the one-site exposures generally produced more BChE inhibition than the closest counterpart
absorbed dose administered as a two-site exposure.

Atropine, 2-PAM, diazepam
administered at 2 h
post-exposure

Threshold

LOAEL – major clinical signs

None

None

LOAEL – minor clinical
signs

None

LOAEL – AChE inhibition

None

4. Discussion
African green monkeys were administered high purity VX using
a ﬁxed duration percutaneous route of exposure that allowed for
the estimation of the absorbed dose of VX. The percutaneous route
of exposure is particularly susceptible to variability from a large
number of factors and any laboratory model of percutaneous exposure is subject to qualiﬁcations that must be considered when
extrapolating the results outside of the laboratory and for comparison to other laboratory studies. In the present study, we were
able to estimate an absorbed dose of VX by quantifying the amount
of VX that could be unequivocally determined to not have been
absorbed (i.e., the residual) and subtracting that amount from the
amount applied to the exposure site. The estimate, however, does
not account for the amount of VX that was decontaminated by the
RSDL applied after the 60 min exposure. Nevertheless, we believe
that this procedure represents a substantial increase in accuracy
for determining dose-effect relationships with percutaneous exposures to VX.
Clinical signs, circulating AChE and BChE, and cognitive behavior
were used to evaluate adverse effects. From the results, threshold
doses can be determined as the lowest observable adverse effect
level (LOAEL) for three categories of adverse effects as described
in Table 1. First, a 6.53 g/kg absorbed dose is the LOAEL for the
inhibition of circulating AChE. This dose resulted in a peak inhibition of ∼35%. The dose below this level produced a small amount
of inhibition (∼8%) but can generally be considered to be within
a range of measurement error and normal day-to-day variability.
The 9.48 g/kg absorbed dose is the LOAEL for minor clinical signs.
In this regard, the only minor clinical sign observed was muscular
fasciculation at and around the site of exposure. The 17.36 g/kg
absorbed dose is the LOAEL for major clinical signs. The subject
receiving this dose showed the major clinical signs of salivation,
tremor and fasciculation and 2 h following the end of the exposure
the subject was treated with rescue therapy. Recovery, however,
was observed on the following day with all clinical signs resolving and behavioral performance on the SPR task not showing a
deﬁcit.
The effects of the highest absorbed dose (39.89 g/kg) evaluated
were severe, and although the subject survived, this dose can be
considered to be in the lethal range, as extensive rescue therapy
was implemented and it is reasonable to infer that such therapy enabled survival. Furthermore, this dose produced persistent
effects, including severe muscular dysfunction, and muscular paral-
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Fig. 2. Circulating AChE activity in blood sampled 30 min (top), 4 h (middle) and
25 h (bottom) following a 60 min percutaneous exposure to VX in African green
monkeys. Abscissae: estimated absorbed dose of VX (g/kg). Activity is expressed
as a percentage of each subject’s control activity (U/ml) assessed during a control
exposure occurring at least seven days prior to VX exposure. Each point represents
the value from a single subject. Closed symbols represent exposures with one site
and open symbols represent exposures with two sites. Dashed lines represent a
linear ﬁt with corresponding Pearson’s correlation coefﬁcient (lower value corresponds to closed symbols and upper value corresponds to open symbols). Asterisks
denote that the subject had received rescue therapy including the oxime 2-PAM HCl
before the sample was drawn.

ysis has been reported previously from VX in guinea pigs (Bide et
al., 2005). Subsequent histology revealed CNS pathology not unlike
that seen following high dose exposure to the nerve agent soman
(see Appendix A). While experimental procedures vary across studies, the absorbed dose administered to this subject is well below the
LD50s of 79.6 g/kg for percutaneous VX in swine (Bjarnason et
al., 2008), 60 g/kg reported for the white pig (from Chilcott et al.,
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Fig. 3. Circulating BChE activity in blood sampled 30 min (top), 4 h (middle) and
25 h (bottom) following a 60 min percutaneous exposure to VX in African green
monkeys. Abscissae: estimated absorbed dose of VX (g/kg). Activity is expressed
as a percentage of each subject’s control activity (U/ml) assessed during a control
exposure occurring at least seven days prior to VX exposure. Each point represents
the value from a single subject. Closed symbols represent exposures with one site
and open symbols represent exposures with two sites. Dashed lines represent a
linear ﬁt with corresponding Pearson’s correlation coefﬁcient (lower value corresponds to closed symbols and upper value corresponds to open symbols). Asterisks
denote that the subject had received rescue therapy including the oxime 2-PAM HCl
before the sample was drawn.

2003) and 125 g/kg in the guinea pig (van der Schans et al., 2003).
In one sense, these results suggest that primates may be more sensitive than the pig, guinea pig or swine. The 39.89 g/kg absorbed
dose in the monkey, however, resulted from a 100 g/kg applied
dose – a value more consistent with the aforementioned studies
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where the LD50 values also refer to applied doses and where no
absorbed dose estimates were made.
Three of the doses evaluated were administered using one and
two exposure sites in separate subjects. The absorbed doses from
equivalent applied doses were similar, but not the same in these
cases. Nevertheless, in general, all three of the two-site exposures
produced less AChE inhibition than the nearest equivalent absorbed
dose for a one-site exposure. Furthermore, none of the two-site
exposures produced any clinical signs. The contrast was most pronounced at the 42.22 g/kg applied dose, which resulted in less
than a 0.65 g/kg difference in absorbed dose, but produced clinical
signs when administered with a one-site exposure and no clinical signs when administered as a two-site exposure. It is generally
thought that two factors relating to the degree of absorption for
the percutaneous route are the concentration gradient and the surface area of the exposure (see Hudson et al., 1979). In the present
comparison, the two-site exposure could be expected to have a
greater surface area but, perhaps, a lower concentration gradient
than the analogous one-site exposure, suggesting that concentration gradient is a dominant factor in this instance. It is notable,
however, that approximately twice as much RSDL was used for the
decontamination with the two-site exposures. Since RSDL is known
(see Manufacturer Safety Data Sheet) to be absorbed beneath the
skin, it is possible that a greater amount of VX below the skin was
decontaminated after the exposure in the two-site instance. In the
absence of determining the exact absorbed doses, only limited conclusions can be drawn in the present case.
As expected, VX produced a dose-dependent decrease in circulating AChE activity. Within the time points sampled, peak
inhibition was generally noted 4 h after the exposure, but was still
substantial 25 h after the exposure. These results are consistent
with the relatively slow rate of AChE inhibition from percutaneous
VX exposure observed in previous studies (e.g., van der Schans et al.,
2003). It is notable that, as expected, in the cases where the oxime
2-PAM HCl was administered as part of a rescue therapy, the inhibition appeared to lessen. Recovery of AChE activity was a relatively
gradual process but was complete with all surviving subjects, showing a return to pre-exposure levels of AChE activity when blood was
sampled 4 weeks following the exposure. In general, the effects of
VX on BChE were similar, albeit to a lesser extent, to those observed
for AChE. That is, VX also produced a dose-dependent decrease in
circulating BChE activity and, within the time points sampled, peak
inhibition was generally noted 4 h after the exposure.
Cognitive and general performance measures from the SPR
behavioral task were unaffected by any doses of VX that did not
produce major clinical signs. Even when circulating AChE was substantially inhibited (35–65%) when blood was sampled 1.5 h before
the behavioral session and approximately 1 h after the behavioral
session, performance on the SPR task was maintained. This result
is consistent with earlier studies in which SPR performance was
maintained with equivalent and even greater AChE inhibition following exposure (either vapor or IM injection) to the nerve agents
soman and sarin in African green and rhesus monkeys (Genovese et
al., 2007b, 2008, 2010). Clearly, a substantial decrease in circulating
AChE activity alone does not correlate with a performance decrease.
In the case of the highest symptomatic dose tested, the general
health of the subject precluded further testing on the SPR task. In
the other case when the VX dose was symptomatic, treatment precluded testing on the day of exposure, but SPR performance on the
next (and subsequent) days did not show a deﬁcit, further evidencing that recovery was substantial in that subject. For the duration
of the study we did not observe any case of a delayed onset deﬁcit
on the SPR task.
The results of the present study characterize the effects of VX
from the percutaneous route of exposure in African green monkeys.
As a chemical warfare nerve agent, the characteristics of VX make

it a likely risk as a contact hazard, and these results extend results
from previous studies using the percutaneous route with rodents
and swine to a non-human primate species. Threshold exposure
doses for multiple adverse effect criteria, including major clinical
signs, were determined and expressed as the applied dose and also
as an estimate of the absorbed dose. The latter approach, in particular, can facilitate interpolation of the results to other laboratory
studies and extrapolation of the results to humans.
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Appendix A. Case report for animal receiving percutaneous
VX (39.89 g/kg estimated absorbed dose)
Subject was a healthy adult female (∼10 years of age) weighing
3.8 kg with no previous history of clinical disease and serologically
negative for Simian retrovirus (SRV), Simian immunodeﬁciency
viruses (SIV), Simian T-cell leukemia (STLV), and Simian foamy
virus (SFV). The subject received a percutaneous exposure to
100 g/kg (377.5 g) VX. Following the 60 min exposure, the residual amount of VX (that which was quantiﬁed on the application disc
and from IPA swabs from the skin around the exposure site) following the exposure was 225.9 g, yielding an absorbed dose estimate
of 39.89 g/kg.
Approximately 30 min after the start of the exposure, chewing and tremor were observed and at 50 min after the start of the
exposure salivation was also observed. Symptom severity increased
dramatically during the last minutes of the exposure, with shallow
and irregular breathing noted and prostration occurring in the last
10 min of the exposure, followed by subsequent collapse. Convulsions were not observed at any time.
After removal of the applicator and decontamination of the
exposure site with RSDL, rescue therapy began and included three
successive IM administrations of atropine sulfate (0.1 mg/kg × 3).
Additionally, 2-PAM HCl (30 mg/kg) and diazepam (4 mg/kg) were
also administered IM. Additional injections of atropine sulfate
(0.1 mg/kg) were given approximately 60 min and 4 h following
the end of the exposure. Eight hours following the exposure,
atropine sulfate (0.05 mg/kg) and 2-PAM HCl (30 mg/kg) were
again administered IM. Lactate Ringer’s solution was administered (approximately 75 ml total) in several injections 2–8 h
post-exposure. At approximately 12 h post-exposure, major symptoms had subsided.
At this time, the subject exhibited clinical signs of generalized
weakness, and slight dyspnea with an inability to maintain normal
erect posture or to initiate the voluntary intake of food or water,
but did retain the ability to ingest food and water if presented
orally. The second day following exposure the subject showed slight
improvement in condition, being more alert and responsive with
the ability to maintain an approximately normal sitting posture
but still exhibiting muscular weakness and reluctance to eat or
drink without assistance. The next four days the subject showed
slight improvement with increased awareness and energy to more
actively take food when directly offered, but still did not initiate
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feeding or drinking. Although the subject regained some muscular
strength and was able to move around the pen, the subject lacked
coordination, appeared to have some degree of hind-limb paralysis
and fatigued quickly, returning to a recumbent position.
AChE activity from blood sampled approximately 4 h postexposure (and notably, after 2-PAM HCl administration) was
measured at 27.7% of control values. Activity from samples taken
72 h, 6 d and 10 d following exposure were observed to be 89.8%,
73.8% and 90.5% of control values, respectively.
Serum chemistry analysis taken six days after exposure showed
an increase of aspartate aminotransferase (AST) (386 U/L), alanine
aminotransferase (ALT) (205 U/L), lactate dehydrogenase (LDH)
(7146 U/L) and creatinine kinase (CK) (14,352 U/L). Although elevations in AST, ALT and LDH can be associated with hepatocellular
injury, the combination with CK deviations suggests degeneration
or necrosis with increased membrane permeability from myopathy. Serum chemistry also showed a slight azotemia (44 mg/dl)
without corresponding increase of creatinine consistent with the
effects of anorexia. On the eighth day after exposure, the clinical
presentation reversed, with return to generalized lethargy, recumbent posture and hypothermia (96.4 ◦ F). A second serum chemistry
analysis (with hemolysis present) showed further elevation in AST
(791 U/L), ALT (235 U/L), an elevation of total bilirubin (1 mg/dl),
but a decline in LDH (3118 U/L) and CK (12,000 U/L).
Ten days following the exposure, the decision was made to perform euthanasia. The animal was placed in a deep surgical plane
and was euthanized using intravenous injection of sodium pentobarbital. Upon veriﬁcation of death, a thoracotomy was performed
to expose the heart. Exsanguination began by opening the right
atrium. The left atrium was cannulated to begin transcardial perfusion. Heparinized saline (500 ml) was infused via the left ventricle
as a buffered clearing solution and followed by 2 L of the ﬁxative solution (Bouin’s ﬂuid). Following perfusion the brain was
removed intact and placed in formalin for 24 h. Using the anterior
commissure (ac) as a landmark, the brain was serially sectioned
and routinely processed for histological examination using hematoxylin and eosin (HE).
A full necropsy was performed with the following tissues examined grossly: brain, heart, lung, liver, digestive tract, kidneys, and
skeletal muscle from both arms and legs. There were no gross
lesions in any of the tissues examined. Sections of the left brain
at 10, 7, and 3 mm rostral to ac and 2, 7, 9, 11, and 13 mm caudal to
ac were examined microscopically. In all sections examined there
were multifocal areas of neuronal necrosis. Neurons were shrunken
and hypereosinophilic with pyknotic nuclei (see Fig. 4A). Surrounding neuropil was often vacuolated and there was prominent gliosis
(Fig. 4B). Occasionally multiple glial cells surrounding degenerate
neurons (neurophagocytosis) were observed (see Fig. 4A). Neuronal changes were predominately conﬁned to the deeper layers of
the neocortex and constituted less than 10% of neurons examined.
Occasionally neuronal necrosis was evident in other areas such as
CA1 of the hippocampus. In general, however, neurons outside of
the cortex were relatively unaffected. White matter lesions were
mild and included axonal degeneration characterized by vacuolation, axonal swelling and digestion chambers (see Fig. 4C). These
lesions were most evident in the longitudinal pontine ﬁbers but
more rarely were evident in the corpus callosum and other white
matter tracks. Subsequent to these ﬁndings the corresponding sections of right brain were similarly examined. Lesions were bilateral
but not necessarily symmetrical.
The histopathologic brain lesions in this animal are consistent
with previous reports of soman-induced neurotoxicity in rhesus macaques. The characteristics of the neuronal necrosis were
morphologically consistent with nerve agent-induced hypoxicischemic injury as reported by Petras (1994) and Baze (1993). In
this case, however, the extent of the lesions was milder and the
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Fig. 4. Photomicrographs depicting various types of neuronal damage in an African
green monkey following percutaneous exposure to VX. (A) CA1 hippocampus: multiple neurons are shrunken and hypereosinophilic with pyknotic nuclei (thin arrows).
Degenerating neuron is surrounded by phagocytic cells (neuronophagia) (thick
arrow). (B) Cerebral cortex, ac +10: vacuolation of the neuropil (arrows) with prominent gliosis and multiple necrotic neurons (arrow heads). (C) Longitudinal pontine
ﬁbers: white matter tracks are vacuolated and contain cellular debris (arrows). All
sections are HE.

distribution appears more limited. This result likely reﬂects, and is
consistent with, the clinical signs exhibited by this animal, which
did not include convulsions, as well as the extensive rescue therapy
administered. In this regard, it is notable that the presence of convulsions following nerve agent exposure has been correlated with
a more extensive neuronal necrosis (e.g., Baze, 1993). Furthermore,
this case illustrates that a symptomatic, non-convulsive and surviving exposure to nerve agent VX produces detectable and consistent
histopathologic lesions observable 10 days following exposure.
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